...
首页> 外文期刊>Molecular Genetics & Genomic Medicine >Evaluation of copy number variant detection from panel‐based next‐generation sequencing data
【24h】

Evaluation of copy number variant detection from panel‐based next‐generation sequencing data

机译:从基于面板的下一代测序数据中评估拷贝数变异检测

获取原文
           

摘要

Background Targeted gene capture and next‐generation sequencing (NGS) has been widely utilized as a robust and cost‐effective approach for detecting small variants among a group of disease genes. Copy number variations (CNV) can also be inferred from the read‐depth information but the accuracy of CNVs called from panel‐based NGS data has not been well evaluated. Methods Sequencing data were acquired from patients underwent routine clinical targeted panel sequencing testing. Pathogenic CNVs detected from targeted panel sequencing data were evaluated using CNVs generated by two clinical accepted platforms, namely chromosome microarray analysis (CMA) and multiple ligation‐dependent probe amplification (MLPA) as benchmarks. CNVkit was used in our study to call CNVs from sequencing data using read‐depth information. CMA and MLPA tests were used to confirm and further assess the size and breakpoints of CNVs. Results The size of CNVs detected using panel‐based NGS data are over 300?kb. The sizes of CNVs detected are slightly larger (102.3% on average) using the NGS platform than using the CMA platform, and the size accuracy improved as the size of variants increases. The breakpoints of CNVs detected using NGS data are quite close (within 2.3% of margin) to the breakpoints detected by CMA. CNVs on sex chromosomes, however, are less concordant between NGS and CMA platforms. Conclusion Copy number variations covering adequate exons on autosomes can be accurately detected using targeted panel sequencing data as using CMA. CNVs detected from sex chromosomes need further evaluation and validation. Except for exon‐level deletion/duplication and CNV on sex chromosome, our data support the use of panel‐based NGS data for routine clinical detection of pathogenic CNVs.
机译:背景技术有针对性的基因捕获和下一代测序(NGS)已被广泛用作检测一组疾病基因中微小变异的可靠且具有成本效益的方法。还可以从读取的深度信息中推断出拷贝数变异(CNV),但尚未对基于面板的NGS数据调用的CNV的准确性进行很好的评估。方法从接受常规临床靶向平板测序测试的患者中获取测序数据。使用两个临床公认的平台(即染色体微阵列分析(CMA)和多重连接依赖性探针扩增(MLPA))生成的CNV,评估了从靶向面板测序数据中检测到的致病性CNV。在我们的研究中,使用CNVkit从使用深度信息的测序数据中调用CNV。使用CMA和MLPA测试来确认并进一步评估CNV的大小和断点。结果使用基于面板的NGS数据检测到的CNV大小超过300?kb。与使用CMA平台相比,使用NGS平台检测到的CNV尺寸稍大(平均102.3%),并且随着变体尺寸的增加,尺寸精度也得到了提高。使用NGS数据检测到的CNV的断点与CMA检测到的断点相当接近(在裕度的2.3%之内)。但是,性染色体上的CNV在NGS和CMA平台之间不太协调。结论使用CMA,可以使用靶向的小组测序数据准确检测常染色体上足够的外显子的拷贝数变异。从性染色体检测到的CNV需要进一步评估和验证。除了外显子水平的缺失/复制和性染色体上的CNV,我们的数据支持使用基于面板的NGS数据进行病原性CNV的常规临床检测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号